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Overexpression of c-Myc is one of the most common alterations in
human cancers, yet it is not clear how this transcription factor acts
to promote malignant transformation. To understand the molec-
ular targets of c-Myc function, we have used an unbiased genome-
wide location-analysis approach to examine the genomic binding
sites of c-Myc in Burkitt’s lymphoma cells. We find that c-Myc
together with its heterodimeric partner, Max, occupy >15% of
gene promoters tested in these cancer cells. The DNA binding of
c-Myc and Max correlates extensively with gene expression
throughout the genome, a hallmark attribute of general transcrip-
tion factors. The c-MycMax heterodimer complexes also colocalize
with transcription factor IID in these cells, further supporting a
general role for overexpressed c-Myc in global gene regulation. In
addition, transcription of a majority of c-Myc target genes exhibits
changes correlated with levels of c-myc mRNA in a diverse set of
tissues and cell lines, supporting the conclusion that c-Myc regu-
lates them. Taken together, these results suggest a general role for
overexpressed c-Myc in global transcriptional regulation in some
cancer cells and point toward molecular mechanisms for c-Myc
function in malignant transformation.
The oncogene c-myc is frequently associated with humanmalignancies and plays a critical role in regulating cell
proliferation, growth, apoptosis, and differentiation (1–6). Stud-
ies in rodent model systems have shown that overexpression of
c-Myc can cause malignant transformation, and that sustained
tumor growth depends on its continued expression (7–12). The
molecular mechanisms by which c-Myc functions to effect tu-
morigenesis have been the subject of extensive research in the
last several decades.
Several lines of evidence suggest that c-Myc may cause trans-
formation through its function as a sequence-specific transcrip-
tion activator. First, the c-Myc protein, along with the Max
protein, can specifically recognize DNA sequences with a core
motif of CACGTG (13, 14). The domain that is required for
c-Myc DNA binding, the basic helix–loop–helix zipper domain,
is essential for its oncogenic transformation (15). Second, c-Myc
possesses an N-terminal transactivation domain. Deletions or
mutations in this domain result in loss of c-Myc transformation
(15). This model implies that c-Myc may cause transformation by
activating a select set of genes that in turn play key roles in
malignant transformation (3). Throughout the years, a large
number of genes targeted by c-Myc regulation either directly or
indirectly have been found. However, such ‘‘transformation’’
genes remain elusive (16).
Some evidence suggests that c-Myc may promote transforma-
tion through different mechanisms. First, the transcriptional
activation potential of c-Myc does not always correlate with its
ability to transform rodent fibroblast cells (4). For example,
several studies showed that mutations in the Myc box II domain
within c-Myc can abrogate its transformation capacity without
affecting c-Myc activation of reporter gene constructs (17, 18).
Second, c-Myc also acts as a transcriptional repressor. The
mechanism of c-Myc-mediated repression is not entirely clear
but in some cases may involve the association of c-MycMax with
transcriptional activators (19–21). Because some of the genes
normally repressed by c-Myc are key cell-cycle regulators, it is
conceivable that c-Myc-mediated repression of these genes may
also contribute to tumorigenesis (22).
More recently, it was shown that c-Myc could directly activate
RNA polymerase (pol) III promoters (23). Because most pol III
promoters lack the canonical c-Myc binding sites, it was demon-
strated that c-Myc-regulated transcription from pol III promoters
occurs through its association with the transcription factor IIIB
(TFIIIB) complex, which is a pol III-specific general transcription
factor. This suggests a potentially broad role for c-Myc in regulating
gene expression and raises the possibility that c-Myc may use a
similar mechanism in regulating pol II promoters.
Identifying the genomic binding sites of c-Myc in cancer cells
should help resolve the long-standing questions regarding mech-
anisms of oncogenic transformation by c-Myc. As an initial effort
to characterize c-Myc DNA binding in vivo, we used a genome-
wide location-analysis approach that allows the determination of
transcription factor-binding sites throughout the genome (24,
25). This method has allowed identification of the DNA-binding
sites in the yeast genome for proteins involved in transcription,
chromatin modification, and DNA replication (26–31). More
recently, the same approach has been used to reveal the pro-
moters directly bound and regulated by the E2F transcription
factors in human cells (32, 33).
Here we report experiments designed to identify genomic
binding sites of c-Myc in Burkitt’s lymphoma cells, which express
high levels of c-Myc due to a chromosomal translocation (34).
We show that the overexpressed c-Myc binds to a large number
of gene promoters in these cancer cells, amounting to nearly 15%
of the loci tested. Furthermore, the DNA binding by c-Myc
generally correlates with global gene transcription activities and
largely coincides with binding of the general transcription factor
TFIID throughout the genome. A majority of the c-Myc target
genes we identified are expressed in other cell types in a manner
correlated with c-myc mRNA levels. Taken together, these
results suggest a rather general role for c-Myc in the regulation
of genome expression in many cancer cells.
Methods
Design and Manufacturing of Human Promoter Microarrays. To con-
duct a comprehensive analysis of the genomic sites of c-Myc in
human cells, we developed a DNA microarray (henceforth
referred to as the hu6K array) that contained PCR products
spanning the proximal promoters of 4,839 human genes chosen
from the NCBI Refseq database. These genes were selected
because their promoters were best-annotated, and there was a
clear function associated with each gene. The DNA fragments
have an average size of 900 bp and typically cover the sequence
from 650 bp upstream to 250 bp downstream of the transcription
start site in a gene. The choice of these regions is based on
previous observations that human transcription factors fre-
quently bind to proximal promoter sequences (32). The hu6K
Abbreviations: pol, RNA polymerase; TF, transcription factor; hu6K, DNA microarray of
6,000 human genomic DNA fragments; ChIP, chromatin immunoprecipitation.
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array also includes 729 coding sequence and 221 genomic regions
1 kb upstream of the transcription start site of a gene. The
latter two categories of sequences serve as internal controls for
the location analysis. The description of all the sequences on the
hu6K array can be found in Array Description, which is published
as supporting information on the PNAS web site, www.pnas.org.
We designed oligonucleotide primers to amplify the genomic
regions discussed above using the PCR. After PCR amplifica-
tion, we purified each DNA fragment, verified the product by
agarose gel electrophoresis, and then spotted the purified
DNA to GAPSII glass slides (Corning) using a contact printer
(Cartesian Technologies, Irvine, CA). After UV crosslinking,
the glass slides were stored under vacuum until use.
Genome-Wide Location Analysis. A detailed protocol for genome-
wide location analysis with mammalian factors can be found in
Supporting Materials and Methods. Briefly, Daudi cells (a gift
from William Sugden, University of Wisconsin, Madison) were
grown in flasks with RPMI medium 1640 supplemented with
10% FBS100 units/ml penicillin100 g/ml streptomycin to a
density of 109 per liter at 37°C in 5% CO2. A total of 109
proliferating Daudi cells were fixed with formaldehyde, har-
vested, and disrupted by sonication. To enrich for target genes
bound to a transcription factor, we immunoprecipitated the
resulting chromatin fragments with polyclonal antibodies that
specifically recognize c-Myc (sc-764), Max (sc-197), E2F1 (sc-
193), TAFII250 (sc-735), or pol II (sc-9001), obtained from Santa
Cruz Biotechnology. After reversal of crosslinks, the purified
and enriched DNA was amplified by ligation-mediated PCR and
subsequently labeled with the Cy5 fluorophore by random
priming. For purposes of normalization, we also performed
ligation-mediated PCR on DNA that was not enriched by
immunoprecipitation and labeled the amplified sample with a
second fluorescent dye, Cy3. Chromatin immunoprecipitation
(ChIP)-enriched and nonenriched (total input) pools of DNA
were mixed with Cot-1 DNA to suppress annealing of repetitive
sequences and hybridized under stringent conditions to a hu6K
array. DNA microarray hybridization was carried out as de-
scribed in ref. 32. The microarray then was analyzed by using a
GenenPix 4000B scanner (Axon Instruments, Foster City, CA).
Data Analysis. Analysis of microarray scanning images was per-
formed according to published protocols (24) with modifications
(see Supporting Materials and Methods, which is published as
supporting information on the PNAS web site). Data from
independent replicate experiments were combined (24). An
average enrichment ratio was calculated for each DNA species
on the array from at least three replicate data sets. The binding
of a factor to DNA was deemed significant if the average P value
was 0.001. By using these criteria, no DNA achieved signifi-
Fig. 1. Genome-wide location analysis of c-Myc- and Max-bound promoters in Burkitt’s lymphoma cells. Five independent experiments were performed to
identify c-Myc or Max bound DNA in formaldehyde-crosslinked Daudi cells. (A) A scatter plot showing the fluorescent intensities for each spot on the hu6K
promoter array in one of the c-Myc location-analysis experiments. A few previously known c-Myc target genes are highlighted. (B and C) Scatter plots
corresponding to one of the Max location-analysis experiments, or the control experiment, in which ChIP was performed in the absence of primary antibodies.
(D) Venn diagram comparing the DNA binding of c-Myc and Max. The data from five experiments were averaged (see Methods), and the genes with a P value
0.001 were counted as targets. Overall, 876 and 931 promoters are bound by c-Myc and Max, respectively. Marked with red in A–C are 776 promoters that are
bound by both. (E) A comparison of the fraction of promoter or coding regions represented on the hu6K array that are bound by c-Myc, Max, or both in Daudi
cells. (F) Conventional ChIP confirms the enrichment of c-MycMax target genes identified in the genome-wide location-analysis experiments. ChIP was
performed with chromatin from Daudi cells by using the indicated primary antibodies, and enriched DNA was amplified with primers corresponding to a random
select number of genes. As a negative control, magnetic beads lacking primary antibodies were used.
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cance in control experiments where input DNA was compared
with the same DNA. The Supporting Raw Data Set containing
processed microarray data is published as supporting informa-
tion on the PNAS web site.
Conventional ChIP. Confirmation of a select number of c-Myc
Max target sites by the conventional ChIP method was per-
formed according to ref. 32. The primers used for amplification
of genomic sequences corresponding to each binding site were
MARS (5-aagtgcgacttgccctaaaa-3 and 5-ccatgcagctgggactaca-
3), ATF4 (5-ctcctttcgtgaggccataa-3 and 5-cgcgcagagaaaacta-
catct-3), TTF2 (5-ggtaaggggctagggtctca-3 and 5-cccagctcaa-
gacctactcg-3), CKN1 (5-ggctctcacttttccctcct-3 and 5-
catgggttggtctcaggatt-3), and control (5-tgggtttggtaggggacata-3
and 5-ctgggctctgctggctta-3). The control PCR product lies
9,595 bp upstream of the transcription start site in the CAD gene.
Results
Widespread DNA Binding by c-MycMax in Burkitt’s Lymphoma Cells.
We first examined the promoter occupancy by c-Myc in Daudi
cells, an established cell line originally derived from a Burkitt’s
lymphoma patient (34, 35). These cells express a high level of
c-Myc and have been used extensively as an experimental system
to study the role of c-Myc in tumorigenesis. We performed five
independent c-Myc location-analysis experiments and averaged
the results using an error model described in Supporting Materials
and Methods (Fig. 1A). The analysis indicates that c-Myc is
associated with the promoters of 876 genes based on a P value
0.001. Because c-Myc binds to DNA as a heterodimer with
Max, we also performed five independent location-analysis
experiments using antibodies that specifically recognize Max. A
total of 931 gene promoters was found to be associated with Max
in vivo (Fig. 1B). As a control, we carried out immunoprecipi-
tation in the absence of specific antibodies. Only 32 gene
promoters were enriched under such conditions, most likely
because of their nonspecific interactions with the magnetic beads
used in these experiments (Fig. 1C).
Several measures suggest that our location analysis is very
robust and highly reliable. First, there is a significant overlap
between the set of gene promoters bound by c-Myc and those
bound by Max. A total of 776 gene promoters bound both
proteins, accounting for 88% of the observed c-Myc binding sites
and 83% of the observed Max binding sites (Fig. 1D). Second,
consistent with previous knowledge, c-Myc and Max rarely bind
to the coding sequences represented on the hu6K array. There
is only 1.1% occupancy by c-Myc and Max for these regions
compared with the 15% occupancy on gene promoters by both
proteins (Fig. 1E). Assuming that observed binding of c-Myc and
Max to coding sequences are false positives, we then estimate
that the false-positive rates for the c-MycMax complex binding
results is 7%, which is in line with previous estimates of
false-positive rates of genome-wide location-analysis experi-
ments (26). Third, we used the conventional ChIP method with
a select set of c-MycMax target genes and confirmed all their
in vivo protein–DNA interactions (Fig. 1F).
Based on this analysis, we estimate that at least 93% of the
gene promoters identified as bound by c-Myc and Max in this
study are true positives. Therefore, the c-MycMax complexes
occupy at least 721 of 776 (93%) gene promoters, or nearly 15%
of the 4,839 gene promoters examined, in Daudi cells. Because
these genes are an unbiased selection of all human genes,
c-MycMax complexes probably bind to close to 15% or 4,500 of
the human genes in these Burkitt’s lymphoma cells.
The DNA Binding of c-Myc and Max Corresponds to Genome Tran-
scription Levels. In most cell types, only a small fraction of the
genome is expressed. Because c-Myc binds to almost 15% of the
human genes in Daudi cells and has a known function as a
transcription activator, one prediction is that c-Myc DNA bind-
ing would correlate with global gene expression in these cells. To
test this hypothesis, we analyzed the correlation of c-Myc or Max
DNA binding and gene expression in Daudi cells. As a measure
of the gene expression, we used previously reported transcrip-
tome data obtained from the Daudi cells (36). We divided the
total gene promoters represented by the hu6K array into 17
groups based on their transcription activity and plotted the
Fig. 2. DNA binding of c-Myc and Max corresponds to genome transcription
levels and resembles the behavior of a general transcription factor. (A) Line
chart showing the correlation between gene-expression levels and promoter
binding by c-Myc, Max, pol II, and E2F1 in Daudi cells. The 4,839 gene
promoters in the hu6K arrays were divided into 17 groups based on their
transcription activities (see Supporting Data Set for Fig. 2, which is published
as supporting information on the PNAS web site). The lower and upper
boundaries of log10-transformed gene-expression values for these groups are
distributed evenly between 1 and 5. The fraction of promoters bound by
each factor in every group is plotted with regard to the log10-transformed
transcription activity for the group. (B) Table showing the pairwise compari-
son of genomic binding profiles of c-Myc, Max, pol II, and E2F1 with respect to
genome expression. P values were calculated based on two-factor ANOVA
analysis without replicate.
Fig. 3. c-Myc and Max colocalize with TFIID in Burkitt’s lymphoma cells. A
Venn diagram compares the gene promoters bound by the c-MycMax com-
plexes and that by TFIID in Daudi cells.
8166  www.pnas.orgcgidoi10.1073pnas.1332764100 Li et al.
fraction of c-Myc-bound promoters in each group with regard to
transcription activities for genes in the group (Fig. 2A). The
analysis indicates a strong correlation between c-Myc DNA
binding and global gene transcription (  0.96). Nearly 50% of
the highly active promoters bound c-Myc in Daudi cells, and the
promoter occupancy gradually decreases in gene groups with
lower promoter activities. Similarly, there is also a strong cor-
relation (  0.95) between the DNA binding by Max and
genome transcription activities (Fig. 2 A).
The extensive correlation between c-Myc’s DNA binding and
global gene transcription not only confirms our prediction of
c-Myc function in Daudi cells but also reveals an extensive role
for this oncogenic transcription factor in global gene regulation,
a role that usually is associated with general transcription factors.
To assess the similarity between the role of c-Myc in genome
transcription and that of a general transcription factor, we
performed genome-wide location-analysis experiments to iden-
tify the genomic binding sites of pol II in Daudi cells. As a
control, we also examined the DNA binding of a typical tran-
scriptional activator, E2F1, in these cells (32). In Fig. 2 A, the
percentage of promoter occupancy by pol II and E2F1 is plotted
with regard to levels of promoter activities in the 17 gene groups
discussed above. Although the DNA binding for both proteins
seems to correlate with genome transcription activities, the
DNA-binding profile of E2F1 with respect to global gene
expression is markedly different from that of pol II (P 0.0047),
c-Myc (P  0.0003), and Max (P  0.0002) when analyzed by
using a two-factor ANOVA method (Fig. 2B). By contrast, the
DNA-binding profile of pol II is indistinguishable from that of
c-Myc (P 0.50) and Max (P 0.44) by using the same analysis.
This result strongly suggests that c-Myc and Max act more like
a general transcription factor than a sequence-specific transcrip-
tion factor in Daudi cells.
c-Myc and Max Colocalize with TFIID on Gene Promoters. The similar
DNA-binding profiles with respect to genome expression be-
tween c-Myc and pol II supports the model that c-Myc may play
a general role in gene transcription in Daudi cells. To further
confirm this and explore the mechanisms of its action in Daudi
cells, we tested whether the DNA binding of c-Myc coincides
with other general transcription factors. In particular, because
c-Myc was shown to interact directly with TATA-box-binding
protein (TBP) (37, 38), the core component of the general
transcription factor TFIID, we tested whether c-Myc colocalizes
with TFIID on gene promoters.
We performed three independent genome-wide location-
analysis experiments to identify the gene promoters associated
with TAFII250, the largest subunit of TFIID, in Daudi cells (39,
Fig. 4. Expression of c-MycMax target genes correlates with levels of c-myc transcript in human tissues and cell lines. (Left) Two-way clustering was performed
on the expression data corresponding to 453 c-MycMax target genes in 46 human tissues and cell lines. The expression data for each gene were log-transformed
and normalized such that the median log expression value is 0. The gene-expression values were represented by using a red-green color scheme, with red
corresponding to higher-than-median expression values and green corresponding to lower-than-median expression values. The expression data corresponding
to different genes are arranged from left to right, and different tissues are arranged from top to bottom. (Right) The c-myc mRNA levels in the corresponding
samples, as measured by using Affymetrix GeneChip, are shown on a bar graph.
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40). The analysis identified a total of 1,157 gene promoters
occupied by TFIID (with a false-positive rate of 6% estimated
from its observed DNA binding to coding sequences). In Fig. 3,
the set of TFIID-bound promoters is compared with promoters
bound by the c-MycMax complexes. A majority (603 of 1,157)
of the promoters occupied by TFIID is also bound by c-Myc
Max, whereas almost all the c-MycMax-bound promoters also
harbor TFIID in Daudi cells. The number of common binding
sites between TFIID and c-MycMax (603) far exceeds a random
overlap between two similar groups (185, with P  0.001, 2
test), suggesting that c-Myc functions together with TFIID in
regulating global gene expression.
Expression of c-MycMax Target Genes Correlates with c-myc mRNA
Levels in Diverse Tissues and Cell Lines. We next asked whether the
promoters bound by c-MycMax are expressed in a c-Myc-
dependent fashion. For this purpose, we compared the expres-
sion of these genes in a variety of human tissues and cell lines in
which c-Myc transcript levels range from undetectable to very
high (36). Among these c-MycMax targets, some genes were not
included in the previous study, and many could not be reliably
detected in the various samples. Therefore, these genes were
excluded from this analysis. The remaining 453 c-Myc target
genes were clustered based on their expression levels in these
tissues and cell lines. As shown in Fig. 4, gene expression from
a majority of the c-MycMax target promoters corresponds with
c-myc mRNA levels (Class A). Genes in this category include
known c-Myc target genes such as CAD, LDHA, p53, and JTV1.
Interestingly, there is a small group of c-MycMax target genes
with expression that inversely correlates with c-Myc mRNA
levels (Class B). Among these genes is the gene encoding the cdk
inhibitor p27, a known target of c-Myc repression. The identities of
these genes can be found in Supporting Data Set for Fig. 4, which is
published as supporting information on the PNAS web site.
Discussion
A General Role for c-Myc in Global Transcriptional Regulation in
Cancer Cells. Overexpression of the c-Myc gene has been associ-
ated with a large number of human malignancies (5). Although
extensive research has been focused on the molecular function
of this protein, it remains unknown how c-Myc promotes ma-
lignant transformation. In this study we attempted to identify the
genomic binding sites for c-Myc and Max complexes in Burkitt’s
lymphoma cells. The results strongly suggest that c-Myc plays a
general role in global gene regulation in these cells. First, we
showed that the c-MycMax complexes bind to a large number
of gene promoters in Burkitt’s lymphoma cells, accounting for
nearly 15% of genes tested. Second, DNA binding of c-Myc
strongly correlates with transcription activities throughout the
genome and resembles the genomic binding profile of pol II but
not that of the sequence-specific transcription factor in the same
cells. Third, c-Myc and Max extensively colocalize with the
general transcription factor TFIID. Finally, expression from
most c-MycMax target promoters corresponds to c-myc tran-
script levels in a diverse panel of human tissues and cell lines.
Based on these observations, we propose a model whereby c-Myc
plays a general role in the regulation of global gene expression
in Burkitt’s lymphoma cells. This model is consistent with the
recent findings that the Drosophila dMycMaxMnt network is
involved in regulating 15% of the genome (41).
Program of Tumorigenesis in Cancer Cells. This extensive role of
c-Myc in gene regulation might underlie tumorigenesis in cells
that overexpress the oncogenic protein. Perhaps in primary cells
or normal tissues, where c-Myc levels are low, the transcription
factor only acts in a sequence-specific manner on a small number
of genes and influences a limited spectrum of cellular behaviors.
In Burkitt’s lymphoma cells or other cancer cells expressing high
levels of c-Myc, on the other hand, c-Myc may boost the global
Table 1. Functional categories of selected c-MycMax target genes
Functional category c-MycMax targets
Signal transduction AKAP10, AKAP9, APPL, ARFRP1, ATF6, ATM, CD164, CD2AP, CD79B, CD97, COPS3, CORO1C, CR2, CREB1, CREBL2, CSF2RB,
CUL5, DAP3, DAXX, DDXBP1, DPYSL3, FUS1, FZD5, GDAP1, GNA12, GNL1, GPRK2L, HCR, IFNAR1, IFNGR1, IL17C, ILK,
ITGB3BP, LANCL1, LNPEP, LOC51657, MADD, MADH3, MAP2K5, MAP2K7, MAP3K5, MAPK7, MAPRE2, MD-1, MKLN1,
MKNK1, MST1R, NFAT5, NFKBIB, NR1D1, NR6A1, P85SPR, PDK1, POR1, PREP, PRKAB1, PRKAB2, PRKCL2, PRKRA, PRKRIR,
PTPN1, PTPN6, PTPRF, RAC2, RAGA, RAP2B, RGS16, RHEB2, RIPK2, RLN1, RNF7, RPS6KA2, RPS6KA5, RPS6KB1, RRAS, RXRB,
SRD5A1, SRP54, SRP68, SRPR, TLE3, TRIP15, ZNF147, and ZNF259
Cell cycle 101F6, APC10, ATM, CCT7, CDC25B, CDC6, CDK6, CDKN1B, CUL5, DNAJA2, FRAP1, GAK, LATS1, LOC51723, MAPRE1, MCM5,
MPHOSPH1, MPHOSPH6, P23, PA2G4, PCNA, PCTK1, PPP2CA, PSMD8, RBBP8, RBL1, SGT1, TOPBP1, TP53, and TSC2
Cell growthproliferation APPL, BARD1, BLZF1, C8FW, CD164, CDC16, CDC25B, CDC6, CDK6, CDKN1B, CIAO1, CKS2, CUL5, DDX1, DNAJA2, ELL, FUS1,
GNA12, HKLP2, ING1, LATS1, MAPRE1, MAPRE2, MD-1, MST1R, MT3, NR6A1, P23, PA2G4, PCNA, PRKRA, PRKRIR, SEI1, SKB1,
SYK, TSPY, XIP, and ZNF259
Cell deathapoptosis ABS, APG12L, ASC, CRADD, CUL5, DAP3, DAXX, MAEA, MAP3K5, MD-1, PDCD8, PTPN6, RAGA, RIPK2, RNF7, SMAC, and TP53
Transporter ABCB6, AKR7A2, ATP5B, ATP5C1, ATP5G2, CACNB1, CLCN2, CLCN3, CLCN6, COX15, DEGS, H6PD, IDH3B, KCNH4, NUP153,
NUP88, PPIA, PRDX5, SLC12A2, SLC1A4, SLC22A3, SLC22A4, SLC25A11, SLC26A4, SLC2A4, SLC31A1, SLC5A6, SLC7A1, SRD5A1,
VDAC2, VDAC3, and XK
Cell adhesion CD164, CD97, CNTN2, CORO1C, DGCR6, FLOT2, ILK, ITGB3BP, MAEA, MKLN1, P84, PTPRF, and SIP2-28
DNA replication CDC6, CHRAC17, MCM3, MCM5, PCNA, POLD4, PPIA, RAD9, TOPBP1, and XIP
DNA repair ABH, ADPRTL2, ADPRTL3, ATM, DDB1, ERCC6, EXO1, FRAP1, G22P1, JTV1, MBD4, MSH2, PCNA, PIR51, PMS1, POLH, PRKDC,
RAD50, RAD54L, RAD9, RBBP8, RECQL, RECQL5, SIP2-28, and TP53
Protein biosynthesis MARS, NACA, PET112L, PYCR1, RPL13, RPL15, RPL18, RPL19, RPL27A, RPL31, RPL37, RPL5, RPL8, RPL9, RPLP1, RPS13, RPS17,
RPS19, RPS20, RPS21, RPS25, RPS26, RPS29, RPS5, RPS6, and SARS
Metabolism ACAD8, ACOX3, AGPS, AKR7A2, ASAH, BCKDHA, BCKDHB, BTN2A1, CARKL, CEPT1, CH25H, CYBA, DPYSL3, EPM2A, GCLC,
GMDS, GNPAT, IDH3B, LOC51172, LOC51601, LTA4H, MAT2A, MGAT2, MOCS2, MT3, MTHFD1, NAGA, NIFS, OAZ1, PDK1,
PDK2, PDK3, PLA2G4B, PLA2G6, PMVK, PP, PRPS2, PRPSAP1, PYCR1, SCLY, SLC2A4, SLC7A1, SREBF2, SSB, ST6GALNACIV,
TOPBP1, and ZNRD1
Oncogenesistumor suppressor ABCB6, AKR7A2, ARMET, BARD1, CUL5, DDX1, DLEU1, DLEU2, HMMR, ING1, LATS1, MADH3, MAPRE1, MEL, MSH2, MYBBP1A,
PMS1, POV1, PPP2CA, PPP2R1B, PTP4A1, RPS19, TP53, TSC2, TSPY, and TTC4
Proteasome POH1, POH1, PSMA1, PSMA5, PSMB1, PSMB5, PSMB7, PSMC4, PSMC5, PSMD10, PSMD3, PSMD5, PSMD7, PSMD8, and PSME3
Transcription factorcofactor ABT1, ATF4, ATF6, CALR, CBF2, CGBP, CIR, CREB1, CREBL2, CRSP6, CSDA, DDXBP1, GABPA, HCF-2, IRF3, LOC51042, LZTR1,
MADH3, MAFF, MYCBP, NFAT5, NFKBIB, NR1D1, POU2F1, PSMC5, RBBP1, RBBP2, RFX5, RNF4, RXRB, SAP18, SAP30, SCML2,
SP4, SUPT5H, TIF1, TMF1, TP53, TRAP150, TRIP13, YY1, ZNF136, ZNF142, ZNF147, ZNF174, ZNF192, ZNF274, ZNF35, and ZNF85
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gene expression and influence a wide spectrum of cellular
pathways by acting on a large number of genes. Many of the
genes we identified as c-MycMax targets play key roles in
signaling, cell-cycle regulation, DNA replication, protein bio-
synthesis, and energy metabolism (Table 1), and their increased
expression as a result from c-Myc overexpression would be
expected to lead to dramatic changes in multiple processes such
as an increase in the overall rate of cell-mass accumulation and
shortened cell cycle. Interestingly, some c-MycMax target genes
we identified have been implicated previously in apoptosis.
Activation of these genes, including p53, Daxx, and Dap3, most
likely will sensitize cells to apoptotic stimuli and necessitate the
accumulation of mutations in these pathways during expansion
of the cell population. It is possible also that an increased rate
of metabolism in Daudi cells may result in higher levels of
reactive oxygen species and DNA damage, which may further
sensitize cells for apoptotic signals (42). Subsequent loss of
function of p53 or BLC2 then could lead to unchecked cell
growth and malignant transformation (1).
Models for c-Myc DNA-Binding Specificity in Cancer Cells. Our anal-
ysis of the sequences of the c-Myc-bound promoters in Burkitt’s
lymphoma cells indicates that the c-Myc recognition motif is not
present in many of these target promoters. For example, only
26% of the promoters contain the CACGTG motif between
1,000 bp upstream of the transcription start site and the trans-
lation start site where it would be expected. Therefore,
CACGTG motif-independent mechanisms may be used by c-
Myc in its binding to gene promoters in Daudi cells. Two models
could explain the widespread DNA binding of c-Myc in Burkitt’s
lymphoma cells.
In the first model, a high level of c-Myc protein may allow it
to bind to sequences that are different from the CACGTG motif
and are not occupied by c-Myc in normal cells. These weak c-Myc
binding sites could be variants of the CACGTG motif or
completely different sequences and occur more frequently in the
genome than the canonical c-Myc binding sites. Although this
model is simple and can explain the increased DNA binding of
c-Myc in Daudi cells, it does not explain the mechanisms of
specificity of c-Myc DNA binding or the strong correlation
between c-Myc DNA binding and global transcription levels.
In the second model, c-Myc may bind to DNA through its
association with other sequence-specific transcription factors or
general transcription factors. Indeed, c-Myc has been shown
previously to directly interact with TATA-box-binding protein
(TBP) (37, 38), and we also demonstrate here that c-Myc DNA
binding coincides with TFIID occupancy on gene promoters.
Taken together, these results suggest that c-Myc may be re-
cruited to gene promoters as part of general transcription
complexes, especially in the absence of the canonical c-Myc
binding sites. A similar mechanism has been implicated recently
in c-Myc’s activation of pol III promoters (23). In this case, c-Myc
binds to TFIIIB, a pol III-specific general transcription factor,
and directly activates pol III transcription.
In conclusion, by analyzing the in vivo binding of c-Myc and
Max to 5,000 gene promoters, we observed that c-Myc is
involved in the regulation of a surprisingly large number of gene
promoters in Burkitt’s lymphoma cells. Such global transcrip-
tional regulatory function by c-Myc may be a key mechanism that
this oncogenic protein uses to promote tumorigenesis.
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